Key Clinical Considerations in HIV Treatment Decisions

Opinion
Video

The panel offers expert perspectives on key factors that inform treatment decisions for patients with HIV.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine


Video content above is prompted by the following question(s):

1. Three drug regimens have been the mainstay of successful HIV-1 treatment since 1996. Although we have seen improvement in the efficacy, adverse effects, and toxicities of contemporary three-drug regimens, even the newest therapies have potential adverse effects. Two-drug combinations are now part of the treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV-1 suppression. Gibas et al 2022
• Can you discuss two versus three drug regimens? Individualized care

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.